Abstract | INTRODUCTION: AREAS COVERED: This review summarizes laboratory changes after IL-6 inhibition and molecular changes in the immune cell. A wide range of diseases is discussed, from those for which the efficacy of IL-6-targeting therapy is approved worldwide to those for which only a small number of clinical cases have been reported. It summarizes the characteristics of the diseases for which IL-6-targeting therapy is expected to be effective. EXPERT OPINION: Clinical evidence has demonstrated that IL-6-targeting therapy is relatively safe; however, it is necessary to be cognizant of early detection of infectious disease, as inhibition of IL-6 masks inflammation. Although many of the cases for which IL-6-targeting therapy was effective or partially effective still require validation through clinical trials, the therapy is suggested as a candidate treatment option for various refractory immune diseases.
|
Authors | Masashi Narazaki, Tadamitsu Kishimoto |
Journal | Expert review of clinical pharmacology
(Expert Rev Clin Pharmacol)
Vol. 15
Issue 5
Pg. 575-592
(May 2022)
ISSN: 1751-2441 [Electronic] England |
PMID | 35791866
(Publication Type: Journal Article, Review)
|
Chemical References |
- Interleukin-6
- Receptors, Interleukin-6
|
Topics |
- Arthritis, Rheumatoid
- Humans
- Immune System Diseases
- Inflammation
- Interleukin-6
- Receptors, Interleukin-6
|